Nature Communications (Mar 2024)

Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages

  • Sonal V. Gidwani,
  • Devarshi Brahmbhatt,
  • Aaron Zomback,
  • Mamie Bassie,
  • Jennifer Martinez,
  • Jian Zhuang,
  • John Schulze,
  • Jason S. McLellan,
  • Roberto Mariani,
  • Peter Alff,
  • Daniela Frasca,
  • Bonnie B. Blomberg,
  • Christopher P. Marshall,
  • Mark A. Yondola

DOI
https://doi.org/10.1038/s41467-024-46295-8
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Viral fusion proteins facilitate cellular infection by fusing viral and cellular membranes, which involves dramatic transitions from their pre- to postfusion conformations. These proteins are among the most protective viral immunogens, but they are metastable which often makes them intractable as subunit vaccine targets. Adapting a natural enzymatic reaction, we harness the structural rigidity that targeted dityrosine crosslinks impart to covalently stabilize fusion proteins in their native conformations. We show that the prefusion conformation of respiratory syncytial virus fusion protein can be stabilized with two engineered dityrosine crosslinks (DT-preF), markedly improving its stability and shelf-life. Furthermore, it has 11X greater potency as compared with the DS-Cav1 stabilized prefusion F protein in immunogenicity studies and overcomes immunosenescence in mice with simply a high-dose formulation on alum.